Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of vildagliptin + metformin fixed-dose combination vs Galvus Met under fed conditions in healthy Thai volunteers
TCTR20231002004Phase 1Unknown
- Sponsor
- International Bio Service
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vildagliptin + metformin, vildagliptin and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by International Bio Service. Primary endpoints: Bioequivalence pharmacokinetic parameters for vildagliptin and Bioequivalence pharmacokinetic parameters for metformin. Status: unknown.
02
Drugs
vildagliptin + metforminvildagliptinmetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on TCTR20231002004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20231002004.